Centiva Capital LP Has $1.94 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Centiva Capital LP grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 156.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,087 shares of the company's stock after purchasing an additional 18,943 shares during the quarter. Centiva Capital LP owned about 0.09% of TransMedics Group worth $1,938,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. Atlas Capital Advisors Inc. bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $31,000. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth approximately $33,000. Sachetta LLC bought a new position in shares of TransMedics Group in the 4th quarter worth $40,000. AlphaQuest LLC acquired a new stake in TransMedics Group in the 4th quarter valued at $52,000. Finally, Arcadia Investment Management Corp MI acquired a new position in TransMedics Group during the fourth quarter worth $72,000. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Up 1.3 %

TransMedics Group stock opened at $93.38 on Wednesday. The firm has a 50 day moving average price of $76.81 and a 200-day moving average price of $75.88. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a market capitalization of $3.16 billion, a P/E ratio of 99.34 and a beta of 1.91.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on TMDX shares. Piper Sandler reiterated an "overweight" rating and set a $105.00 price objective (up from $90.00) on shares of TransMedics Group in a report on Tuesday, April 29th. Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $124.20.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.